Wedbush Has Lowered Expectations for Aprea Therapeutics (NASDAQ:APRE) Stock Price

Aprea Therapeutics (NASDAQ:APRE) had its target price dropped by equities researchers at Wedbush from $11.00 to $7.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. Zacks Research lowered Aprea Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target (down previously from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.50.

Aprea Therapeutics Stock Performance

Shares of APRE stock opened at $0.64 on Tuesday. The stock has a market capitalization of $4.49 million, a price-to-earnings ratio of -0.30 and a beta of 1.48. Aprea Therapeutics has a one year low of $0.55 and a one year high of $3.72. The company’s 50-day simple moving average is $0.88 and its 200-day simple moving average is $1.27.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36). The business had revenue of $0.00 million for the quarter. Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%. As a group, research analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current year.

Insiders Place Their Bets

In other Aprea Therapeutics news, Director Marc Duey bought 21,459 shares of Aprea Therapeutics stock in a transaction dated Wednesday, December 10th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $25,107.03. Following the purchase, the director owned 256,155 shares of the company’s stock, valued at $299,701.35. The trade was a 9.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.63% of the stock is currently owned by corporate insiders.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.